<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002020</url>
  </required_header>
  <id_info>
    <org_study_id>014L</org_study_id>
    <secondary_id>28</secondary_id>
    <nct_id>NCT00002020</nct_id>
  </id_info>
  <brief_title>Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC</brief_title>
  <official_title>Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerance, in patients with severe clinical manifestations of HIV&#xD;
      infection, of zidovudine (AZT) administered daily for 48 weeks as a low dose every 4 hours or&#xD;
      a higher dose every 12 hours.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
        - Prophylaxis or treatment for Pneumocystis carinii pneumonia (PCP) consisting of either&#xD;
        trimethoprim / sulfamethoxazole, aerosolized pentamidine, pyrimethamine / sulfadoxine, or&#xD;
        dapsone allowed at the discretion of the investigator.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Any immediately life-threatening infection or medical condition present at the time of&#xD;
             study entry.&#xD;
&#xD;
          -  Any active opportunistic or other infection requiring chronic therapy at the time of&#xD;
             study entry. Patients with PCP may be randomized to study medication following a&#xD;
             minimum 7-day course of therapy resulting in stabilization of their disease. Patients&#xD;
             with stabilized disease must have a fever &lt; 39 C for at least 48 hours, pO2 (on room&#xD;
             air ) = or &gt; 60 mm, and an Arterial/alveolar gradient = or &lt; 30 mm.&#xD;
&#xD;
          -  Diagnosis of AIDS Dementia Complex.&#xD;
&#xD;
          -  Received more than 4 weeks of antiretroviral therapy or who previously discontinued&#xD;
             antiretroviral therapy due to drug related toxicity.&#xD;
&#xD;
          -  Diseases and conditions listed in Exclusion Co-existing Conditions.&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  Seropositive for HIV infection documented by any federally licensed ELISA and&#xD;
             confirmed by Western blot.&#xD;
&#xD;
          -  Advanced HIV disease or AIDS-related complex.&#xD;
&#xD;
          -  Ability to give informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  AIDS with malignant disease likely to require cytotoxic chemotherapy.&#xD;
&#xD;
          -  Diagnosis of AIDS Dementia Complex.&#xD;
&#xD;
          -  Impaired renal function ( Creatinine clearance &lt; 50 ml/min/1.73m2 or serum creatinine&#xD;
             = or &gt; 2 mg/dl).&#xD;
&#xD;
          -  Impaired hepatic function ( ALT = or &gt; 5 x upper limit of normal).&#xD;
&#xD;
          -  Fever &gt; 39 C at entry.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Any other experimental therapy.&#xD;
&#xD;
          -  Drugs which cause significant bone marrow suppression.&#xD;
&#xD;
          -  Cytolytic chemotherapy.&#xD;
&#xD;
          -  Drugs which cause significant nephrotoxicity or hepatotoxicity.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation therapy (with the exception of electron beam therapy to an area &lt; 100 cm2).&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 2 weeks of study entry:&#xD;
&#xD;
        - Any other experimental therapy. Drugs which cause significant bone marrow suppression.&#xD;
        Cytolytic chemotherapy. Drugs which cause significant nephrotoxicity or hepatotoxicity.&#xD;
&#xD;
        Excluded within 4 weeks of entry:&#xD;
&#xD;
        - Immunomodulating agents, including pharmacological doses of steroids for more than 10&#xD;
        days (except for management of severe PCP in which case duration should not exceed 21&#xD;
        days). Interferon. Isoprinosine. IL-2.&#xD;
&#xD;
        Excluded within 8 weeks of entry:&#xD;
&#xD;
        -&#xD;
&#xD;
        Antiretroviral agents including:&#xD;
&#xD;
        - Ribavirin. Dideoxycytidine (ddC). Dideoxyadenosine (ddA). Didanosine (ddI). Foscarnet.&#xD;
        Dextran Sulfate. AL-721. Retrovir (Zidovudine, AZT) for greater than 4 weeks or within 90&#xD;
        days of study entry, or patients who originally discontinued Retrovir due to drug-related&#xD;
        toxicity. Drugs metabolized by hepatic glucuronidation may alter the metabolism of Retrovir&#xD;
        and should not be used chronically.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation therapy (with the exception of electron beam therapy to an area &lt; 100 cm2)&#xD;
             within 2 weeks of study entry.&#xD;
&#xD;
        Known active drug or alcohol abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Univ of Arizona / Health Science Ctr</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Univ Med School</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook County Hosp</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Presbyterian - Saint Luke's Med Ctr</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Missouri at Kansas City School of Medicine</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Jersey Community Research Initiative</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>071032842</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of New Mexico Hlth Sciences Ctr / Dept of Med</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northshore Hosp / Cornell Univ</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Pennsylvania / HIV Clinic</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ TX Galveston Med Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan Veterans Administration Med Ctr</name>
      <address>
        <city>San Juan</city>
        <zip>009275800</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 1992</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

